AstraZeneca

Extracted Attributes

• Employees

  70,600

• R&D Centers

  Cambridge, UK; Gothenburg, Sweden; Gaithersburg, Maryland, US; Warsaw, Poland

• Company Type

  Multinational pharmaceutical and biotechnology company

• Headquarters

  Cambridge, UK

• Therapeutic Areas

  Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, Gastrointestinal, Infection, Neuroscience, Rare Diseases, Inflammation

• Nasdaq-100 Company

  Yes

• FTSE 100 Constituent

  Yes

• Primary Stock Listing

  London Stock Exchange (LSE)

• Secondary Stock Listings

  Nasdaq Stockholm, American Nasdaq

• Planned US Investment (by 2030)

  $50 billion

• Total Revenue (Year ending 2024)

  $54.1 billion

• Total Revenue Growth (Year ending 2024)

  >18%

• Investment in Science (Year ending 2024)

  $13.6 billion

Timeline

• Astra AB, one of AstraZeneca's predecessor companies, was formed by a group of doctors and apothecaries in Södertälje, Sweden. (Source: Wikipedia, Wikidata)

  1913-01-01

• Zeneca Group, the British predecessor, was formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries. (Source: Wikipedia, DBPedia)

  1993-01-01

• AstraZeneca plc was formed through the merger of Sweden's Astra AB and the UK's Zeneca Group. (Source: Summary, Wikipedia, DBPedia)

  1999-01-01

• AstraZeneca acquired Cambridge Antibody Technology. (Source: Wikipedia, DBPedia)

  2006-01-01

• AstraZeneca acquired MedImmune. (Source: Wikipedia, DBPedia)

  2007-01-01

• AstraZeneca acquired Spirogen. (Source: Wikipedia, DBPedia)

  2013-01-01

• MedImmune (an AstraZeneca subsidiary) acquired Definiens. (Source: Wikipedia, DBPedia)

  2014-01-01

• AstraZeneca became involved in the development of the Oxford-AstraZeneca COVID-19 vaccine. (Source: Summary, DBPedia)

  2020-XX-XX

• Reported $54.1 billion in total revenue, >18% total revenue growth, and $13.6 billion invested in science for the fiscal year ending. (Source: Web Search Results)

  2024-12-31

• Opened a new cell therapy manufacturing facility in Rockville, Maryland, US. (Source: Web Search Results)

  2025-XX-XX

• Plans to invest $50 billion in the United States by this year, aiming to create tens of thousands of new jobs. (Source: Web Search Results)

  2030-XX-XX

• Noted for major investments related to onshoring, supporting the United States' strategy to win the global AI Arms Race against China. (Source: Related Document)

  Recent

AstraZeneca

AstraZeneca plc () (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Its British counterpart, Zeneca PLC was formed in 1993 when ICI divested its pharmaceuticals businesses; Astra AB and Zeneca PLC merged six years later, with the chosen headquarters in the United Kingdom. AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide.

Web Search Results

• AstraZeneca plans to invest $50 billion in America for medicines ...

  AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the [...] AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. [...] AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”

• AstraZeneca | Company Overview & News - Forbes

  # AstraZeneca Upgrade to gain access to exclusive features and add your profile photo. Learn More Forbes does not accept payment for placement on lists. AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

• AstraZeneca - Wikipedia

  AstraZeneca develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas. [...] oral Bruton's tyrosine kinase inhibitor, acalabrutinib (ACP-196), which under development at that time. In 2015, AstraZenica was the eighth-largest drug company in the world based on sales revenue. [...] AstraZeneca has its corporate headquarters in Cambridge, United Kingdom, and its main research and development (R&D) centres are in Cambridge (UK), Gaithersburg (Maryland, US), Mölndal in Gothenburg (Sweden), and Warsaw (Poland). In 2025 the company opened a new cell therapy manufacturing facility in Rockville, Maryland. ### Headquarters

• AstraZeneca US

  At AstraZeneca, we are leading a revolution in oncology to redefine cancer care for the millions of Americans living with cancer. It’s a lofty ambition. But we know that as with every great journey, the road always starts with one—one indication that can change the course of disease for a patient, one person living with cancer that benefits from our support services, one access barrier that we can help to overcome, one system to transform in partnership with the community—and then another, [...] Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

• About Our Company - AstraZeneca

  Through the power of science and innovation, we are taking action on climate and nature, health equity and health systems resilience. We collaborate with governments, health systems, patient groups, academia and NGO’s to focus our shared efforts where we can have the greatest impact — on local, regional and global health. ### How we do business [...] ### We are dedicated to being a great place to work. One where everyone who chooses to work at our company is able to make a difference to patients, a meaningful contribution to society and a positive impact on our planet. ### We foster an environment where our people feel they belong and are empowered to reach their full potential, perform at their best and make a valued contribution to the enterprise. ## Join AstraZeneca and help us deliver life-changing medicines [...] ## AstraZeneca at a glance ### $54.1bn ### Total Revenue\ ### >18% ### Total Revenue growth\ ### $13.6bn ### invested in our science\ \year ending 31 December 2024 ## Our Purpose ### We push the boundaries of science to deliver life-changing medicines. Our Purpose underpins everything we do. It gives us a reason to come to work every day. It reminds us why we exist as a company. It helps us deliver benefits to patients and create value for shareholders. ## Our Values

• Image

  

• Country

  Sweden

• Employees

  70,600

• Instance Of

  Q891723

• Headquarters

  Cambridge

• Inception Date

  1/1/1913

AstraZeneca plc (/ˌæstrəˈzɛnəkə/) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden and Gaithersburg in Maryland, U.S. AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index.